baber/WOPTO huggingface dataset:
Patent NZ-567652-A (NZ)
Title: A method for removing 2,4,6 trichloroanisole (TCA) from wine using a zeolite
Inventor: CUNNINGHAM JOHN
IPC: C12H1/04
Filed: 2006-11-03
Abstract: A method for removing 2,4,6 Trichloroanisole (TCA) from a beverage without aroma and flavour scalping of components other than TCA is disclosed, wherein the method comprises the step of: contacting said beverage with a molecular sieve which is a Zeolite-Y (Faujasite) having a Si/AI ratio of at least 5, wherein the beverage is wine wherein said Zeolite-Y is administered at a concentration of from 0.02 to 0.1 g of Zeolite-Y per liter of wine. Also disclosed is a closure device capable of removing TCA present in a beverage container comprising a molecular sieve which is a Zeolite-Y (Faujasite) having a Si/A1 ratio of at least 5, wherein the beverage is wine and the closure device is arranged to administer Zeolite-Y at a concentration of from 0.02 to 0.1 g of Zeolite-Y per liter of wine.
Patent NZ-567659-A (NZ)
Title: Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
Inventor: WASHBURN WILLIAM N
IPC: A61K31/519
Filed: 2006-10-26
Abstract: Disclosed are 4-oxo-thieno[3,2-d]pyrimidine derivatives as respresented by the general formula (I), wherein; R1 is independently selected from the group consisting of hydrogen, halogen, alkyl, cycloalkyl, phenyl, naphthyl, CF3, CN, NR7R7, OR6 and SR6; R2 is selected from the group consisting of hydrogen and alkyl; R4 is G-D2-Zn; G is selected from the group consisting of O, S or CR7R7; D2 is selected from the group consisting of a direct bond, alkyl, cycloalkyl and a 4 to 6-membered non-basic heterocycle; Z is selected from the group consisting of hydroxyl, cycloalkyl, cycloalkoxy, OCOR6, CN, OSO2R6, SR6, SOR6, SO2R6, CO2R7, OPO(OR6)2 and COR6; m is an integer from 0 to 1; n is an integer from 1 to 3; and wherein the other substituents are as defined herein. The compounds are useful as pharmaceutical active agents, and particularly as melanin concentrating hormone receptor-1 antagonists.
Patent NZ-570886-A (NZ)
Title: Method and compositions to reduce polygalacturonase expression in plants for increasing storage-life of fruit
Inventor: ATKINSON ROSS GRAHAM
IPC: A01H4/00
Filed: 2008-08-29
Abstract: A method for producing a plant with a fruit having increased post-harvest storage life. The method comprises reducing the expression or activity in the plant of a polypeptide with the amino acid sequence SEQ ID NO: 1 (Malua domestica polygalaturonase, MdPG1), or a variant thereof having at least 70% sequence identity. The expression or activity of the polypeptide encoded by SEQ ID NO: 1 is reduced by a polynucleotide capable of reducing the expression of the polypeptide; in particular the polynucleotide is an RNAi construct. The fruit can be an apple and has at least one of the following characteristics: (a) increased firmness, (b) reduced water loss, (c) reduced cell separation, (d) increased juiciness, (e) increased crispiness, (f) increased waxiness, or (g) reduced susceptibility to necrophytic pathogens during or after post-harvest storage.
Patent NZ-572983-A (NZ)
Title: Phosphinate modulators of toll-like receptor 7
Inventor: CHONG LEE S
IPC: A61K31/66
Filed: 2007-07-06
Abstract: Disclosed are phosphinate compounds represented by general formula I or II, wherein the substituents are defined within the specification. Also disclosed is the use of the compounds of formula I or II for treating or preventing a viral infection in a patient.
Patent NZ-577770-A (NZ)
Title: Method for arrangement for animal management
Inventor: DAVIS KENDRA
IPC: A01K1/12
Filed: 2009-06-15
Abstract: A method for managing animals allowed to move in a specified area, the area comprising several grazing paddocks 12a, 12b, 12c, 12d, 12e, 12f where the animals can graze, a milking area 13 where the animals can be milked, and a waiting area 14 accessible from the grazing paddocks. The waiting area 14 is where the animals wait to be milked. The method comprises the steps of identifying which animals are to visit the milking area 13, checking whether the selected animals have milking permission, and only allowing, guiding or forcing the animals with milking permission or who fulfill other criteria to enter the waiting area 14. The method provides a more efficient milking system for pasture based animals.
Patent NZ-578297-A (NZ)
Title: Boron-containing small molecules
Inventor: BAKER STEPHEN J
IPC: A61K31/343
Filed: 2006-02-16
Abstract: A method of treating an infection in a non-human animal is disclosed, wherein the method comprises administering to the animal a therapeutically effective amount of 1,3-dihydro-5-chloro-1-hydroxy-2,1-benzoxaborole, or a pharmaceutically acceptable salt thereof sufficient to treat said infection. Also disclosed is a pharmaceutical composition, comprising: (a) 1,3-dihydro-5- chloro-1-hydroxy-2,1-benzoxaborole, or a salt thereof; and (b) a pharmaceutically acceptable excipient, wherein said pharmaceutical composition is formulated for topical administration to an animal suffering from an infection by a microorganism.
Patent NZ-589443-A (NZ)
Title: Powder dispenser for mixing said powder with liquid
Inventor: FREI CHRISTIAN
IPC: B06B1/00
Filed: 2009-05-27
Abstract: 589443 Disclosed is a dosing device (1) for the preparation of a food composition or coffee. The dosing device comprises supply means (2) for providing a soluble powder, a dosing member (3) which is rotatably mounted and which comprises at least one recessed portion (4) for receiving powder supplied by the supply means (2) in a first rotational position and discharging powder in a second rotational position, and tapping means (5) driven by the rotation of the dosing member (3) and designed to induce a reciprocating force on the supply means (2).
Patent NZ-589713-A (NZ)
Title: Arrangement to ensure an air gap in an electric machine does not close causing the rotor and stator to touch
Inventor: STIESDAL HENRIK
IPC: F03D11/00
Filed: 2010-12-03
Abstract: Arrangement to ensure an air gap (119) in an electric machine (101) is maintained is disclosed. The electrical machine contains a stator arrangement (108) and a rotor arrangement (114). The stator arrangement contains a lamination stack (110), which is constructed to support at least one winding of a stator-coil (11). The rotor arrangement rotates around a longitudinal axis and contains a number of permanent magnets (118). The magnets of the rotor interact with the winding of the stator to generate electrical power. The air gap is defined by the distance between the permanent magnets of the rotor and the lamination stack of the stator. The lamination stack and supported winding are on opposite sides of the air gap to the magnets along a length of the lamination stack, the cross section of the air gap changing along this length, so the air gap is not uniform. The cross section of the air gap is configured by a change in the heights (H11, H12) of the permanent magnets and/or by a change in the heights of base plates (117), which are used to carry the permanent magnets.
Patent NZ-591875-A (NZ)
Title: Device for measuring silica concentration and conductivity of steam in a geothermal power generation plant
Inventor: MYOUGAN ICHIRO
IPC: F03G4/00
Filed: 2009-10-02
Abstract: 591875 Disclosed is an automatic steam characteristics-measuring device (1) for continuously measuring the characteristics of steam taken from a production well. The device has a silica monitor (16) for measuring a concentration of silica included in a condensate obtained by cooling steam taken from under the ground; and an electrical conductivity meter (19) for automatically measuring the electrical conductivity of the condensate. The device also includes a data processing transmitter for automatically transmitting data measured by the monitor and meter. A geothermal power-generating device equipped with the automatic steam characteristics-measuring device (1) is also provided.
Patent NZ-592612-A (NZ)
Title: Vasoactive intestinal peptide (VIP) Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X for the treatment of kidney disorders
Inventor: DUGGAN KAREN ANNETTE
IPC: A61K38/08
Filed: 2009-10-16
Abstract: Disclosed is the use of a peptide of the following sequence: Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X, wherein X is absent or selected from the group consisting of: -Leu-Arg-Lys-Gln; -Leu-Arg-Lys-Gln-Met-Ala-Val-Lys; and -Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn, or conservative substitutions thereof for the manufacture of a medicament for the prophylactic or therapeutic treatment of chronic kidney disease in a subject, wherein the chronic kidney disease is associated with kidney fibrosis.
Patent NZ-594981-A (NZ)
Title: Hepatitis c virus inhibitors
Inventor: LOPEZ OMAR D
IPC: A61K31/403
Filed: 2010-03-29
Abstract: 594981 Disclosed are compounds of Formula (I) as defined in the specification and compositions comprising such compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these compounds or a composition comprising such compounds. Specific embodiments of the compounds include: methyl ((1S)-1-(((2S)-2-(4-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl)arnino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazo-1-4-yl)-1,1'-bi(3-cyclohexen-lyl)-4-yl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate, and methyl ((1R)-2-((2S)-2-(4-(4-(4-(2-((2S)-1-((2R)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-2-pyrrolidinyl)-1H-imidazol-4-yl)bicyclo[2.2.2]oct-1-yl)phenyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)-2-oxo-1-phenylethyl)carbamate;
Patent NZ-603524-A (NZ)
Title: Can manufacture
Inventor: MONRO STUART
IPC: B21D22/30
Filed: 2011-04-13
Abstract: 603524 A method and apparatus are disclosed which are suitable for use in the manufacture of two-piece metal containers. In particular, a press is disclosed which makes cup sections from metal sheet using a combination of drawing and stretching operations. The cups resulting from the press have the advantage of having a base thickness that is thinner relative to the ingoing gauge of the metal sheet.
Patent NZ-611606-A (NZ)
Title: Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
Inventor: OSTERLOH IAN
IPC: A61K31/20
Filed: 2011-11-28
Abstract: Discloses a pharmaceutical composition comprising eicosapentaenoic acid, or an ester thereof, wherein the pharmaceutical composition contains less than about 1%, by weight, of proteins, if any.
Patent NZ-615531-A (NZ)
Title: Method and apparatus for detecting and treating heart failure
Inventor: SCHINDHELM KLAUS HENRY
IPC: A61B5/02
Filed: 2012-06-27
Abstract: 615331 A method and apparatus are disclosed for detecting and treating heart failure using data from a non-contact sensor and determining with a processor change in a heart failure condition.
Patent NZ-617099-A (NZ)
Title: Scalable primate pluripotent stem cell aggregate suspension culture and differentiation thereof
Inventor: SCHULZ THOMAS C
IPC: C12N5/0735
Filed: 2013-10-29
Abstract: Discloses is a roller bottle comprising a culture of primate pluripotent stem cell (pPSC) aggregates in suspension in a physiologically acceptable medium.
Patent NZ-626157-A (NZ)
Title: Allocation of gpu resources across multiple clients
Inventor: URBACH JULIAN MICHAEL
IPC: G06F15/16
Filed: 2011-06-10
Abstract: Disclosed is a method including hosting, on a computer system (120), a plurality of application instances (131A-131D) corresponding to a remote client application. A network connection (150A-150D) to each of the remote client applications is maintained for which an application instance (131A-131D) is hosted and resources of a graphics processing unit (121) of the computer system (120) are allocated between at least two of the remote client applications. The graphical output of the application instances (131A-131D)corresponding to the at least two of the remote client applications are then concurrently rendered. The method further includes utilizing the resources of the graphics processing unit (121) of the computer system (120) and transmitting the rendered graphical output to the at least two of the remote client applications over the respective network connections (150A-150D).
Patent NZ-631218-A (NZ)
Title: Combination of an oxidant and a photoactivator for the healing of wounds
Inventor: LOUPIS NIKOLAOS
IPC: A23L11/00
Filed: 2009-11-06
Abstract: Disclosed herein is a composition comprising: at least one oxidant selected from hydrogen peroxide, carbamide peroxide, and benzoyl peroxide; at least one photoactivator that is a fluorescent dye; at least one healing factor selected from hyaluronic acid, glucosamine and allantoin; in association with a pharmaceutically acceptable carrier; wherein the fluorescent dye is not Eosin. Said composition may further comprise a hydrophilic gelling agent selected from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. Also disclosed is a method for wound healing which comprises the steps of: (a) topically applying on a non-human animal’s wound a composition comprising at least one oxidant, wherein the at least one oxidant is chosen from hydrogen peroxide, carbamide peroxide and benzoyl peroxide; at least one photoactivator that is a fluorescent dye, wherein the fluorescent dye is not Eosin; at least one healing factor selected from hyaluronic acid, glucosamine and allantoin; and (b) exposing said skin of step (a) to actinic light for a time sufficient for said photoactivator to cause activation of said oxidant.
Patent NZ-707486-A (NZ)
Title: Pyrrolobenzodiazepine - anti-psma antibody conjugates
Inventor: HOWARD PHILIP WILSON
IPC: A61P35/00
Filed: 2013-10-11
Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile N10 protecting group in the form of a linker to an antibody, wherein the antibody is an antibody that binds to PSMA, the antibody comprises a VH domain paired with a VL domain and the paired VH and VL domains have specified sequences. The drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to 8. The present invention is suitable for use in providing a PBD compound to a preferred site in a subject. The conjugate allows the release of an active PBD compound that does not retain any part of the linker.
Patent NZ-711015-A (NZ)
Title: Formulations of organic compounds
Inventor: KOCHHAR CHARU
IPC: A61P35/00
Filed: 2014-03-04
Abstract: The present invention relates to solid pharmaceutical compositions comprising the phosphatidylinositol 3-kinase inhibitor compound 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine or a pharmaceutically acceptable salt thereof, sodium stearyl fumarate, and optionally at least one additional pharmaceutically acceptable carrier. The present invention also relates to the processes for their preparation and to their use as medicaments for the treatment of cancer.
Patent NZ-711123-A (NZ)
Title: Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
Inventor: XU JEAN
IPC: C07D487/04
Filed: 2012-11-30
Abstract: Disclosed is a solid form of the compound 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one represented by the structural formula shown herein, having an X-ray powder diffraction pattern with one or more peaks expressed in two-theta at approximately 8.3, 8.8, 13.2, 16.5, 17.7, 18.2, 21.7 or 26.5 degrees; and having XRPD peaks at approximately 8.3, 13.2, 18.2 or 21.7 degrees, and a DSC thermogram with an endotherm at a peak temperature of about 199 ºC.
Patent NZ-711958-A (NZ)
Title: Compositions and methods of using islet neogenesis peptides and analogs thereof
Inventor: LIU LIPING
IPC: C07K7/02
Filed: 2014-03-14
Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
Patent NZ-716197-A (NZ)
Title: Processing cellulosic or lignocellulosic materials
Inventor: MEDOFF MARSHALL
IPC: C12P19/04
Filed: 2009-12-16
Abstract: The claims relate to a method of enhancing oxidative molecular weight reduction in cellulosic or lignocellulosic material, the method comprising: providing a first cellulosic or lignocellulosic material having a first peak molecular weight value, the first cellulosic or lignocellulosic material having been exposed to irradiation from a beam of particles comprising oxygen ions; and initiating or sustaining a plurality of chain scission reactions with the first cellulosic or lignocellulosic material and one or more oxidants comprising ozone generated in-situ by the beam of particles, the chain scission reactions carried out, at least in part, in the presence of one or more compounds comprising one or more naturally-occurring, nonradioactive group 5, 6, 8, 9, 10 or 11 elements, the one or more elements participating in a Fenton-type reaction with the one or more oxidants, and hydroxyl radicals generated by the beam of particles and/or in the Fenton-type reaction then reacting with the first cellulosic or lignocellulosic material, to produce a second cellulosic or lignocellulosic material having a second peak molecular weight value lower than the first peak molecular weight value, wherein the first cellulosic or lignocellulosic material comprises one or more functional groups imparted thereon by the beam of particles.
Patent NZ-721918-A (NZ)
Title: Modified serpins for the treatment of bleeding disorders
Inventor: HUNTINGTON JAMES
IPC: C07K14/81
Filed: 2014-12-15
Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P1’ and P2 residues, and optionally within the P1 and/or P4 residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
Patent NZ-722198-A (NZ)
Title: Universal self-limiting electrosurgical return electrode
Inventor: EHNINGER MICHAEL
IPC: A61B18/16
Filed: 2014-12-26
Abstract: A self-limiting electrosurgical return electrode for use with electrosurgical procedures is disclosed. The return electrode includes a conductive element and pads disposed on opposing sides of the conductive element. The conductive element, optionally in combination with the pads, is configured to limit the density of electrical current that passes from a patient to the return electrode. The conductive element and the pads can cooperate to define two separate working surfaces on opposing sides of the return electrode. The return electrode can also be safely used with patients of substantially any size and without requiring adjustments to the power settings of an electrosurgical generator.
Patent NZ-723177-A (NZ)
Title: Implant comprising fgf-18
Inventor: GUEHRING HANS
IPC: A61L27/24
Filed: 2015-02-20
Abstract: The invention relates to the field of pharmaceutical compositions. More particularly it is directed to a substance delivery system (or implant), comprising collagen and glycosaminoglycan scaffolds or membranes, further comprising an anabolic drug, such as a Fibroblast Growth Factor 18 (FGF-18) compound, to methods of producing such delivery system, as well as use thereof. The implants according to the invention are for use for the treatment of cartilage disorders, such as osteoarthritis, cartilage injury or osteochondral defects
Patent NZ-727185-A (NZ)
Title: Phosphatidylinositol 3-kinase inhibitors
Inventor: PATEL LEENA
IPC: C07D491/107
Filed: 2015-06-23
Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R1, R2, R3 R4, R5, R6 and R7 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more ΡI3Κ isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.
Patent NZ-730609-A (NZ)
Title: Product and package with a photosensitive use-evident feature
Inventor: SMITH ROGER
IPC: B65D55/02
Filed: 2013-11-05
Abstract: It is desirable to provide a package including a container that indicates whether the container has been used and, thus, will provide evidence of efforts to repackage the container with counterfeit product. Disclosed herein is a package that includes: a container having an interior and a base, and a closure removably closing said container, characterized by means for indicating that said package has been opened from its original factory sealed condition by removing said closure from said container. The means includes: a drop indicator operatively coupled to said container and constructed at least in part of photochromic material that is responsive to ultraviolet (UV) light so as to irreversibly darken upon exposure thereto.
Patent NZ-743064-A (NZ)
Title: Fire resistant electric cable
Inventor: FOSS-PEDERSEN GEIR
IPC: H01B7/02
Filed: 2015-12-09
Abstract: Electric cables used in industrial facilities, such as onshore and offshore plants, or in public infrastructures, such as underground lines, require high fire resistance properties to maintain operation of the facilities or infrastructures for a certain period of time to allow evacuation of the people before the fire breaks out. Provided is a fire resistant medium and high voltage electric cable (100), comprising a conductor (110) surrounded in the following order by a first semiconductive layer (120), an insulating layer (130), a second semiconductive layer (140), a conductive screen (150), a heat block layer (165), a rubberised glass fibre tape, and an outer sheath (200). The cable is further comprised of a first glass fibre tape (170) radially interposed between the conductive screen (150) and the rubberised glass fibre tape (190) in a radially outer position with respect to the heat block layer (165). The presented configuration of the fire resistant medium and high voltage electric cable improves the thermal insulation properties of the cable and avoids an outflow of the melted insulation when subjected to high temperatures such as a fire, thus maintaining the insulation properties of the cable.